Wen-Chyi Shyu, PhD

● CEO, BRIM Biotechnology inc., Taiwan
● With more than three decades of experience working in the life sciences industry, Dr. Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company.  Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management.  She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.
● Shyu is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.
● Shyu received her PhD from the College of Pharmacy at the University of Connecticut, USA, and carried out her postdoctoral fellowship training at the University of Florida, USA.